2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2582

Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure
Abstract Number: 2583

Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Ankylosing Spondylitis: A Pooled Analysis from the Secukinumab Phase 3 Trial Program
Abstract Number: 2584

Low Incidence of Both New-Onset and Flares of Uveitis in Secukinumab-Treated Patients with Ankylosing Spondylitis: Clinical Trial and Post-Marketing Safety Analysis
Abstract Number: 2585

Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
Abstract Number: 2586

Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis
Abstract Number: 2587

The Impact of Tumor Necrosis Factor Inhibitors on Diabetes Mellitus Among Patients with Inflammatory Arthritis
Abstract Number: 2588

Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis
Abstract Number: 2589

Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 2590

Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 2591

Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry
Abstract Number: 2592

Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry
Abstract Number: 2593

Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis : Results from a Randomized, Double-Blind, Phase III Study
Abstract Number: 2594

Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Abstract Number: 2595

Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Abstract Number: 2596

Real-World Long-Term Effectiveness of Switching between Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].